EUVIMEDEUVIMED entdecken
Open Access

N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model

Naomi Lomeli, Diana C Pearre, Javier Lepe, Donovan A Argueta, Mya A Arellano, Joni L Ricks-Oddie, Kalpna Gupta, Daniela A Bota

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2024.217405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Naomi Lomeli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of California Irvine, Irvine, CA, USA. Hauptthemen laut MEDLINE: Cisplatin, Acetylcysteine, Ovarian Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NINDS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-related cognitive impairment (CRCI) is prevalent among cancer patients. A critical disparity in the CRCI field is that most pre-clinical studies have been conducted on young cancer-free male rodents, although CRCI predominantly affects breast cancer and ovarian cancer women survivors. Since oxidative stress is widely implicated in the development of CRCI, we developed an ovarian cancer xenograft rat model of CRCI in Cr:NIH-RNU female rats to examine whether administration of the antioxidant N-acetylcysteine (NAC) prevents cisplatin-induced CRCI without altering its anti-cancer efficacy. In vitro, delayed treatment with NAC (10 h) following cisplatin treatment in the human ovarian cancer cell line SKOV3.ip1 did not decrease cisplatin's anti-cancer efficacy while mitigating hippocampal dendritic branching damage and neuronal apoptosis. Rats received subcutaneous and intraperitoneal implantation of SKOV3.ip1 cells. Rats received one cisplatin (5 mg/kg) injection every two weeks for a total of four cycles, with or without NAC (250 mg/kg/day), given for five consecutive days during cisplatin treatment. NAC was administered 10 h after cisplatin, based on our in vitro data. Cognitive testing was performed six to seven weeks after treatment cessation. In vivo, cognitive impairments were observed in tumor-bearing rats in the vehicle and cisplatin-treatment groups, while delayed NAC prevented cognitive impairments. Delayed NAC administration did not affect cisplatin-induced tumor volume reduction. Our study supports using NAC to mitigate cisplatin-induced CRCI through the novel development of an ovarian cancer rodent model. This study highlights the importance of developing clinically relevant tumor-bearing models to elucidate the underlying mechanisms associated with CRCI, which will aid in identifying potential therapeutic agents for preventing CRCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinAcetylcysteineOvarian NeoplasmsAntineoplastic AgentsCognitionChemotherapy-Related Cognitive ImpairmentAnimalsFemaleHumansRatsCell Line, TumorApoptosisDisease Models, AnimalXenograft Model Antitumor AssaysOxidative StressAntioxidantsBehavior, Animal

Stichwörter der Autor:innen

Cancer-related cognitive impairments (CRCIChemo-brain)CisplatinGlutathioneHippocampal neuronsN-acetylcysteineNeurotoxicityOvarian cancerPSD-95

Substanzen

CisplatinAcetylcysteineAntineoplastic AgentsAntioxidants

Autor:innen und Institutionen

  • Department of Neurology, University of California Irvine, Irvine, CA, USA.
  • Gynecologic Oncology, Providence Cancer Institute, Burbank, CA, USA.
  • Department of Pathology, University of California Irvine, Irvine, CA, USA.
  • Department of Medicine, Division of Hematology/Oncology, University of California Irvine, Irvine, CA, USA.
  • Center for Statistical Consulting, Department of Statistics, University of California Irvine, Irvine, CA, USA; Biostatistics, Epidemiology and Research Design Unit, Institute for Clinical and Translational Sciences, Uni…
  • Department of Neurology, University of California Irvine, Irvine, CA, USA; Department of Pathology, University of California Irvine, Irvine, CA, USA; Chao Family Comprehensive Cancer Center, University of California Irv…

Förderung

  • NCATS NIH HHS
  • NINDS NIH HHS
  • NCI NIH HHS
  • NCCIH NIH HHS
  • National Center for Complementary and Integrative Health
  • National Center for Advancing Translational Sciences
  • National Cancer Institute
  • Urban Child Institute

Zitieren

APA

Lomeli, N., Pearre, D. C., Lepe, J., Argueta, D. A., Arellano, M. A., Ricks-Oddie, J. L., Gupta, K., & Bota, D. A. (2025). N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217405

Vancouver

Lomeli N, Pearre DC, Lepe J, Argueta DA, Arellano MA, Ricks-Oddie JL, et al. N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217405

BibTeX
@article{Lomeli2025,
  author = {Lomeli, Naomi and Pearre, Diana C and Lepe, Javier and Argueta, Donovan A and Arellano, Mya A and Ricks-Oddie, Joni L and Gupta, Kalpna and Bota, Daniela A},
  title = {N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2024.217405}
}
Kostenlos starten →